1028.80
0.27%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended